Navajo Meal Program Makes Headway in Heart Failure: MUTTON-HF A culturally tailored meal plan featuring traditional foods, as well as other support, reduced hospital stays within 90 days.

A culturally tailored, food-based intervention program for people in the Navajo Nation with HF can significantly reduce hospitalizations, according to data from the MUTTON-HF study. www.tctmd.com/news/navajo-...
#ACC2026

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate The controversial findings had interventional cardiologists looking for answers, with operator experience coming into focus.

During #ACC2026, three trials comparing IVUS with angiography for PCI guidance in patients with complex coronary artery disease—DKCRUSH VIII, OPTIMAL, and IVUS-CHIP—uncovered surprising results where only DKCRUSH VIII showed an advantage to using intravascular imaging. www.tctmd.com/news/two-neu...

An antisense oligonucleotide, olezarsen, doesn't reduce noncalcified coronary plaque volume, despite lowering triglycerides and cholesterol among patients with moderate hypertriglyceridemia and elevated CV risk, based on the Essence-TIMI 73b trial. www.tctmd.com/news/olezars...
#ACC2026

La FDA autorise l'orforglipron pour la gestion du poids L'orforglipron d'Eli Lilly a été approuvé pour les adultes souffrant d'obésité ou de surpoids et présentant au moins une comorbidité.

La FDA autorise l'aGLP-1 orforglipron pour la gestion du poids #ACC2026
https://mdsc.pe/3NVr4CN

Le vaccin contre le zona diminue le risque cardiovasculaire Les patients atteints d'une maladie cardiovasculaire athéroscléreuse qui avaient reçu le vaccin contre le zona ont vu leur risque d'événements cardiaques indésirables majeurs diminuer.

Le vaccin contre le zona protège contre les événements cardiaques graves #ACC2026
https://mdsc.pe/4c2PgfG

In a comparison of multiple add-ons to statin therapy, the phase III CORALreef AddOn trial shows the oral PCSK9 inhibitor enlicitide outperformed several different nonstatin combinations. www.tctmd.com/news/oral-pc...
#ACC2026

In this Beyond the Data, watch @mmamas1973.bsky.social and Luca Testa discuss the OPTIMAL trial during the recent #ACC2026, which compared IVUS versus angiographic guidance for PCI in unprotected left main disease. www.tctmd.com/videos/beyon...

Financial Support After Hospital Discharge Boosts HFrEF Outcomes: FUND-HF Low-income patients receiving a debit card spent most of the money on things upstream of medical care like food and utilities.

www.tctmd.com/news/financi... #ACC2026 #CardioSky #HeartFailure

GoFreshRx, THRIVE Trials Show BP Benefits of ‘Food as Medicine’ Helping patients get groceries and make meals while staying on a DASH-approved diet not only helped, but people liked it, too.

Two different trials—GoFreshRx and THRIVE—have shown the benefits of Dietary Approaches to Stop Hypertension (DASH)-aligned meals for controlling BP in Black adults with hypertension. www.tctmd.com/news/gofresh...
#ACC2026

Novel Cerebral Protection Device Matches Up Well With Sentinel in TAVI The question remains: what will it take to prove that any protection device is having a meaningful impact on stroke risk?

The novel cerebral protection device Emboliner provides comparable results to those obtained with the Sentinel cerebral protection system when used during transfemoral TAVI, according to the PROTECT H2H trial. www.tctmd.com/news/novel-c...
#ACC2026

What is the impact of IVUS- vs angiography-guided complex high-risk PCI? @mmamas1973.bsky.social and Roberto Diletti talk about the IVUS-CHIP trial during the recent #ACC2026 on this Beyond the Data. Watch the full video now: www.tctmd.com/videos/beyon...

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients The results run counter to ABYSS but align with other data showing beta-blockers shouldn’t continue indefinitely after MI.

Stabilized patients who are taken off of long-term beta-blocker therapy post-MI without evidence of heart failure or left ventricular dysfunction do not experience any adverse outcomes, based on results from the SMART-DECISION trial. www.tctmd.com/news/smart-d...
#ACC2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI The results, which are mostly relevant to an older population, address a common dilemma for aortic stenosis patients with CAD.

Patients with both coronary artery disease and aortic stenosis who are undergoing TAVI can safely defer revascularization, based on new data from the PRO-TAVI trial. www.tctmd.com/news/deferri...
#ACC2026

Transcatheter ViV a Solid Option for Failed Mitral Bioprostheses: SURViV The first RCT to compare valve-in-valve vs redo surgery reassures, especially for regions where rheumatic valve disease is prevalent.

For certain patients who require treatment for failed mitral bioprostheses, transcatheter mitral valve-in-valve (ViV) procedures are found to be safe, according to data from the SURViV trial. More here: www.tctmd.com/news/transca...
#ACC2026

Excited to share that our poster has been accepted for presentation at the 2026 American Control Conference! 🥳

A huge thank you to Prof. Yanwen Xu and Prof. Wenbin Wan for their mentorship.

See you in New Orleans! 🎷

#ACC2026 #AmericanControlConference

How does using noninvasive fractional flow reserve versus conventional wire-based physiology assessments affect treatment decisions? Watch @mmamas1973.bsky.social, William Fearon, and Joost Daemen discuss the FAST III and ALL RISE trials during the recent #ACC2026. www.tctmd.com/videos/beyon...

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial In carefully selected patients with CTOs, symptom-driven PCI does provide a benefit when done by experienced operators.

For patients with CTO, treatment with PCI greatly reduces angina symptoms and angina frequency, based on data from the first placebo-controlled trial, ORBITA-CTO. www.tctmd.com/news/orbita-...
#ACC2026

We are delighted to announce the ACC 2026 Trainee Award Winners. These awards recognize trainees whose high-quality abstracts showcase the potential of the next generation of cytogeneticists.

Congratulations to our winners!

Register today: buff.ly/eLMu1L3

#ACC2026 #AmericanCytogenomics

Left atrial appendage closure fails to match medical therapy in high-risk AF Left atrial appendage closure fails to match medical therapy for preventing stroke and major events in high-risk atrial fibrillation, the CLOSURE-AF trial shows.

From #ACC2026 - Left atrial appendage closure fails to match medical therapy for preventing #stroke and major events in high-risk atrial fibrillation, the CLOSURE-AF trial shows.

👉 buff.ly/wXa91qR

#CardioSky #MedNews

On this Beyond the Data, @mmamas1973.bsky.social, Navin Kapur, and Sunil Rao talk about the STEMI-DTU trial during the recent #ACC2026. Watch the full video now: www.tctmd.com/videos/beyon...

Adding evolocumab to statins reduces MACE even without overt atherosclerosis Adding evolocumab to background statin therapy substantially reduces the risk for a major adverse cardiovascular event in high-risk patients with diabetes who do not have significant atherosclerosis.

From #ACC2026 - Adding evolocumab to background statin therapy substantially reduces the risk for MACE in high-risk patients with #diabetes who do not have significant atherosclerosis.

👉 buff.ly/T8IcYzB

#CardioSky #MedNews

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV Investigators suggest LDL targets typically reserved for secondary prevention are best in high-risk patients with diabetes.

The addition of the PCSK9 inhibitor evolocumab to statin therapy is very effective for reducing major CV events in high-risk patients without ASCVD when compared with statins alone, based on analysis from the VESALIUS-CV trial. www.tctmd.com/news/pcsk9-i...
#ACC2026

ACC : focus sur les études Tri.Fr et SCOUT-HCM L’essai français Tri.Fr montre le bénéfice à 30 mois du TriClip sur les hospitalisations et l’étude SCOUT-HCM évalue le mavacamten chez les 12–18 ans atteints de cardiomyopathie hypertrophique obstruc...

#ACC2026 : l’essai français TRi-FR montre le bénéfice à 30 mois du TriClip sur les hospitalisations et SCOUT-HCM évalue le mavacamten chez les 12–18 ans atteints de cardiomyopathie hypertrophique.
francais.medscape.com/viewarticle/acc-focus-%C...

Six raisons pour lesquelles CHAMPION-AF ne devrait pas modifier les pratiques L'essai comparatif entre la fermeture percutanée de l'appendice auriculaire gauche et les anticoagulants oraux directs chez les patients atteints de fibrillation auriculaire est qualifié de ...

Six raisons pour lesquelles CHAMPION-AF ne devrait pas modifier les pratiques #ACC2026
https://mdsc.pe/4sIGn0B

🔬 #ACC2026: Meilenstein in der Behandlung der #Lungenembolie mit intermediärem Risiko! ✨
📊 Studie: HI-PEITHO
🗣️ Speaker: Prof. Stavros Konstantinides
Prof. Christos Rammos berichtet und kommentiert:
➡️ herzmedizin.de/fuer-aerzte-...
#Herzmedizinde #Kardiologie #Cardiosky

▶️ #ACC2026: Video-on-Demand jetzt exklusiv auf HERZMEDIZIN verfügbar! 📺 Expertinnen und Experten stellen Neues vom ACC.2026 zu Prävention, Interventionen, Herzinsuffizienz und Rhythmologie vor.
➡️ herzmedizin.de/fuer-aerzte-...
#Herzmedizinde #DGK #Kardiologie #CardioSky

Records were made to be broken! 📈

The ACC 2026 Meeting Program has officially arrived, fueled by a record-breaking number of abstract submissions!

🔗 Link in comments to view the full schedule! 👇

#ACC2026 #AmericanCytogenomics #Cytogenomics #Cytogenetics #GeneticsConference

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension Repeat injections of the angiotensinogen-targeted drug didn’t reduce BP more than a single dose.

For patients with treatment-resistant hypertension, monthly injections of tonlamarsen lower AGT levels better than a single dose, but the impact on BP is complex, according to results from the KARDINAL trial. www.tctmd.com/news/kardina...
#ACC2026

🔬 #ACC2026: New Data on the Role of LAAC in Stroke Prevention – A New Impulse for Clinical Decision-Making?
📊 Studie: CHAMPION-AF
🗣️ Speaker: Prof. Saibal Kar
Dr. Nina C. Wunderlich (Asklepios Klinik Langen, Germany) comments.
➡️ herzmedizin.de/fuer-aerzte-...
#Herzmedizinde #Kardiologie #Cardiosky

HI-PEITHO: Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE The intervention group had a 61% lower risk of decompensation and other hard outcomes at 7 days.

Patients with acute intermediate-risk pulmonary embolism have better short-term outcomes with ultrasound-facilitated, catheter-directed fibrinolysis plus heparin-based anticoagulation compared with anticoagulation alone, based on data from the HI-PEITHO trial. www.tctmd.com/news/hi-peit...
#ACC2026